

Guidelines on Infective Endocarditis 2015 (TF01) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Antunes Manuel J	Nothing to be declared (2013-2014-2015)
Bongiorni Maria Grazia	Nothing to be declared (2013-2014) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Johnson & Johnson : ablation (2015) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : pacing (2015) - Boston Scientific : s-icd (2015) D - Research funding (departmental or institutional). - Johnson & Johnson : af ablation (2015) - Boehringer-Ingelheim : afib anticoag. (2015) - St Jude Medical : biventricular pacing (2015) - Boston Scientific : icd lead (2015)
Casalta Jean-Paul	Nothing to be declared (2013-2014-2015)
Del Zotti Francesco	Nothing to be declared (2013-2014-2015)
Dulgheru Raluca Elena	Nothing to be declared (2013-2014) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Actelion Belgium : Pulmonary hypertension (2015)
El Khoury Gebrine	Nothing to be declared (2013-2014-2015)
Erba Paola Anna	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Philogen SpA : Immunoconjugates (2013-2014) - Advanced Accelerator Applications - AAA : Radiopharmaceuticals (2013-2014) - Sigma Tau : radiopharmaceuticals (2015) - Philogen SpA : radiopharmaceuticals (2015) - GE Healthcare : radiopharmaceuticals and equipments (2015) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Philogen SpA : Immunoconjugates (2013-2014)

Guidelines on Infective Endocarditis 2015 (TF01) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Erba Paola Anna	<ul style="list-style-type: none"> - Advanced Accelerator Applications - AAA : Radiopharmaceuticals (2013-2014) - GE Healthcare : radiopharmaceuticals/equipment (2013-2014) - Immunomedics : Radiopharmaceuticals (2014) - Sigma Tau : Radiopharmaceuticals (2014-2015) - Philogen SpA : Radiopharmaceuticals (2015) - AAA : radiopharmaceuticals (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Philogen SpA : Immunoconjugates (2013-2014) - Sigma Tau : Radiopharmaceuticals (2014) - Immunomedics : Radiopharmaceuticals (2014) - Philogen SpA : radiopharmaceuticals (2015)
Habib Gilbert	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : pulmonary hypertension (2013-2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : pulmonary hypertension (2013-2014-2015) - Abbott : Mitraclip (2015) - Actelion : Pulmonary Hypertension (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Genzyme : Fabry's disease (2015)
lung Bernard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : rivaroxaban (2013) - Boehringer-Ingelheim : dabigatran (2013-2014-2015) - Edwards Lifesciences : heart valve prosthesis (2013-2014-2015) - Abbott : Mitraclip (2013-2014-2015)
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Heart Failure (2013)

Guidelines on Infective Endocarditis 2015 (TF01) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<ul style="list-style-type: none"> - Abbott : MitraClip (2013) - Menarini : nebivolol (2014) - St Jude Medical : Heart Failure (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astrazeneca : Dyslipidemia (2013) - Boston Scientific : CRT (2014) - Servier : procoralan (2014) - Daiichi Sankyo : Teaching course on imaging (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Actelion : Pulmonary Hypertension (2013)
Miro Jose M	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - ViiV : Antiretrovirals (2013-2014) - Elsevier : Associated Editor, Infectious Diseases and Clinical Microbiology Journal (2013-2014) - Gilead : Antiretrovirals (2013-2014-2015) - Bristol Myers Squibb : Antiretrovirals (2013-2014-2015) - Merck Sharp & Dohme : Antiretrovirals (2013-2014-2015) - AbbiVie : Antiretrovirals (2013-2014-2015) - Novartis : Daptomycin (2013-2014-2015) - Cubist : Daptomycin (2013-2014-2015) - Pfizer : Linezolid (2013-2014-2015) - Theravance : Telavancin (2013-2014-2015) - ViiV Healthcare : Antiretrovirals (2014-2015) - Janssen-Cilag : Antiretrovirals (2015)

Guidelines on Infective Endocarditis 2015 (TF01) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Miro Jose M	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Antiretrovirals (2013-2014-2015) - Merck Sharp & Dohme : Antiretrovirals (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Novartis : Daptomycin (2013-2014-2015) - Cubist : Daptomycin (2013-2014-2015) - National Institute for Health (NIH), Bethesda, MA, USA : Antibiotics (2014-2015) - ViiV Healthcare : Antiretrovirals (2015)
Mulder Barbara Jm	Nothing to be declared (2013-2014-2015)
Plonska-Gosciniak Edyta	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : lecturing (2013) - Servier : lecturing (2013) - Sanofi Aventis : lecturer (2014) - Servier : lecturer (2014-2015) - Polpharma : lecturer (2015)
Price Susanna	<p>Nothing to be declared (2014-2015)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medtronic : educational contract (2013) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott : Mltraclip (2013)
Roos-Hesselink Jolien W	Nothing to be declared (2013-2014-2015)
Snygg-Martin Ulrika	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Ceftazidim-avibactam (2014-2015)
Thuny Franck	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Philips : imaging products (2013-2014-2015)

Guidelines on Infective Endocarditis 2015 (TF01) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Thuny Franck	<ul style="list-style-type: none"> - Daiichi Sankyo : pharmceutic products (2013-2014-2015) - Novartis : pharmceutic products (2013-2014-2015) - Pfizer : pharmceutic products (2013-2014-2015)
Tornos Mas Pilar	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Recordati International : Lipazo (2014-2015)
Vilacosta Isidro	<p>Nothing to be declared (2013-2014-2015)</p>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichii : Atrial Fib (2013) - Merck Sharp & Dohme : Lipid Lowering (2013) - Philips : 3D echo (2014) - Toshiba medical imaging : fusion imaging 3D echo CT (2014) - Astra Zeneca : Speaker fee for 1 talk in 2014 (2014) - MSD : CV risk factors (2014-2015) - Abbott : Lecturing (2015) - Astra Zeneca : Lecturing (2015) - Pfizer : Lecturing (2015) - Sorin Group : Respicardia echo protocol (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - European Research FP7 : CV Imaging (2013) - Servier : Imaging in ISchemic patients (2013) - Siemens Healthcare : 3d echo software and free style echo (2014-2015) - Toshiba medical imaging : Fusion Imaging (2015)

Guidelines on Infective Endocarditis 2015 (TF01) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	C - Receipt of royalties for intellectual property. - Springer : ESC Textbook of CV Imaging (2013) D - Research funding (departmental or institutional). - Amgen : Clinical trial (2014-2015) - Novartis : Clinical trial (2014-2015) - Ikaria : Clinical trial (2014-2015)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Aakhus Svend	<p>Nothing to be declared (2015)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Drug therapy (2013) - GE Healthcare /advisory board : Ultrasound Cardiology (2014)
Aboyans Victor	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antithrombotics (2014) - Sanofi Aventis : Hyperlipidemia (2014) - Boehringer-Ingelheim : Oral anticoagulation (2014) - Pfizer/BMS alliance : Oral anticoagulation (2014) - Novartis : Hypertension (2014-2015) - Bayer Healthcare : Oral anticoagulation (2014-2015) - Merck Sharp & Dohme : Antithrombotics (2015)
Agewall Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Böhringer Ingelheim : Anticoagulatn treatment (2013) - Roche Diagnostics : Cardiac markers (2013) - Orion : Heart failure (2013) - Pfizer : Lipids (2013) - Sanofi Aventis : Lipids (2013) - Siemens Healthcare : Markers (2013) - Astra Zeneca : Platelet inhibition (2013-2014-2015) - Thermo Fischer Scientific : Cardiac markers (2014-2015)
Athanasopoulos George	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulation (2013-2014-2015)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Athanassopoulos George	D - Research funding (departmental or institutional). - GlaxoSmithKline : pulmonary hypertension (2013-2014-2015)
Aytekin Saide	Nothing to be declared (2014-2015) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Actelion Honoraria : PAH (2013)
Baccar Hedi	Nothing to be declared (2014-2015) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : advisory board (2013)
Benzer Werner	D - Research funding (departmental or institutional). - Boston Scientific : Interventional Cardiology (2013-2014-2015)
Bouma Berto	Nothing to be declared (2013-2014-2015)
Broekhuizen Berna Ditte Lidewij	Nothing to be declared (2013-2014-2015)
Bruun Niels Eske	Nothing to be declared (2013-2014) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Leo Pharma : Hypertension (2015)
Bueno Hector	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BMS/Pfizer : Apixaban (2013) - Roche Pharma : Dalcetrapib (2013) - Novartis : Relaxin (2013) - Bayer Healthcare : Aspirin, rivaroxaban (2013-2014-2015) - Sanofi Aventis : Clopidogrel (2013-2014-2015) - Daiichi Sankyo : Prasugrel (2013-2014-2015) - Eli Lilly : Prasugrel (2013-2014-2015) - Astra Zeneca : Ticagrelor (2013-2014-2015) - Novartis : Serelaxin (2014)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> - Pfizer : Apixaban (2014-2015) - Bristol Myers Squibb : Apixaban (2014-2015) - Servier : ivabradine (2014-2015) - Menarini : Ranolazine (2014-2015) - Abbott : Absorb stent (2015) - Novartis : Serelaxin, ACZ696 (2015) - Ferrer Internacional : Trinomia (polypill) (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2013-2014-2015)
Carerj Scipione	Nothing to be declared (2013-2014-2015)
Cassar Demarco Daniela	Nothing to be declared (2013-2014-2015)
Cecchi Enrico	Nothing to be declared (2013-2014-2015)
Chachalis Georgios	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier, ASTRAZENECA : PHARMACEUTICAL (2013) - Merck Sharp & Dohme : EZETIMIBE (2014) - Boehringer-Ingelheim : NOACS (2014) - Pfizer : NOACS (2014) - Pfizer : DRUG (APIXABAN) (2015) - Boehringer-Ingelheim : DRUGS (DABIGATRAN) (2015)
Cosyns Bernard	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Apixaban (2013-2014-2015) - Pfizer : Apixaban (2014-2015)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Cosyns Bernard	<ul style="list-style-type: none"> - Therabel : molsidomine (2014-2015) - Zambon : Zanicombo (2014-2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Dabigatran (2014-2015) - Johnson & Johnson : MMR nanobodies (2014-2015) - St Jude Medical : pacing (2014-2015)
De Backer Julie	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : NOAC's (2014) - Actelion : Pulmonary Hypertension (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Funds for Scientific Research Flanders : NA (2013-2014-2015) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Special Research Funds of the Ghent University : NA (2013-2014-2015)
De Bonis Michele	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medtronic : valve prostheses (2013-2014-2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Cardiac valves annuloplasty rings and prostheses (2013-2014)
Delahaye Francois	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - GlaxoSmithKline : SOLID-TIMI52 (2013-2014) - MSD : IMPROVE-IT (2014-2015)
Dimopoulos Konstantinos	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Pulmonary Hypertension (2013-2014-2015) - Pfizer : Pulmonary Hypertension (2013-2015) - GlaxoSmithKline : Pulmonary Hypertension (2013-2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Pfizer : Pulmonary Hypertension (2013) - Actelion : Pulmonary Hypertension (2014)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Dimopoulos Konstantinos	D - Research funding (departmental or institutional). - Bayer : Pulmonary Hypertension (2015) - Pfizer : Pulmonary Hypertension (2015) - Actelion : Pulmonary Hypertension (2015)
Donal Erwan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bristol Myers Squibb : atrial fibrillation (2013-2014-2015) - Novartis : heart failure (2013-2014-2015) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GE Healthcare : imaging (2013-2014-2015)
Donova Temenuga Ivanova	Nothing to be declared (2013-2014-2015)
Drexel Heinz	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck and others : diabetes, hypertension, lipids (2013-2014) - Merck Sharp & Dohme and others : diabetes, hypertension, lipids (2015)
Erol Cetin	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Hypertension (2013-2014-2015) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini : Hypertension (2013-2014-2015)
Flachskampf Frank Arnold	Nothing to be declared (2013-2014-2015)
Gale Christopher Peter	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Acute Coronary Syndrome (2013-2014) - Novartis : Anti VEGF therapy (2013-2014) - Astra Zeneca : Ticagrelor (2015)
Gavina Cristina	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : dabigatran (2013-2014-2015) - Bayer : rivaroxaban (2013-2014-2015) - Astra Zeneca : ticagrelor (2013-2014-2015)
Georgiou Georgios C	Nothing to be declared (2013-2014-2015)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hall Roger	<p>Nothing to be declared (2013-2015)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Advisory board Drug trials (2014) - British Medical Journal : Lectures (2014) - Cardia trial : Research trial (2014)
Halvorsen Sigrun	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Anti-thrombotic treatment (2013) - Bristol Myers Squibb : Antithrombotic treatment (2013-2014) - Astra Zeneca : Anti-thrombotic treatment (2013-2014) - Boehringer-Ingelheim : Anti-thrombotic treatment (2013-2014) - Pfizer : Anti-thrombotic treatment (2013-2014) - Bayer AG : Anti-thrombotic treatment (2013-2014) - Eli Lilly : Anti-thrombotic treatment (2013-2014) - Sanofi Aventis : Cholesterol lowering treatment (2013-2014) - Merck Sharp & Dohme : Cholesterol lowering treatment (2014) - Astra Zeneca : Speaker fees (2015) - Boehringer-Ingelheim : Speaker fees (2015) - Pfizer : Speaker fees (2015) - Sanofi Aventis : Speaker fees (2015) - Bristol Myers Squibb : Speaker fees (2015) - Merck Sharp & Dohme : Speaker fees (2015) - Bayer AG : Speaker fees (2015)
Hoen Bruno	<p>Nothing to be declared (2013-2014-2015)</p>

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hrafnkelsdottir Thordis	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer in Iceland : 24 hour blood pressure speaker fees (2013) - Novartis : Canakinumab (2013-2014-2015) - icepharma : Cancer treatment (2015)
Hricak Vasil	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet drug (2013) - Astra Zeneca : Antiplatelets treatment - ticagrelor (2014) - Eli Lilly : Antiplatelets tratment - prehospital strategy -prasugrel (2015) - Astra Zeneca : Antiplatelets treatment -tikagrelor (2015) - Roche Diagnostics : hs-troponin for ACS (2015)
Jahangirov Tofig	Nothing to be declared (2013-2014-2015)
Jonkaitiene Regina	Nothing to be declared (2013-2014-2015)
Jovanova Silvana	Nothing to be declared (2013-2014-2015)
Kamzola Ginta	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis Pharma Serv. AG : Echocardiography in terms of clinical trial (2013) - Pfizer : Heart failure. Speaker fee (2013) - Merck Serono : Heart failure. Speaker fee (2013) - Servier : Heart failure, Speaker fee (2013-2014-2015) - Grindeks : Cardiology; Consultancy (2014) - Novartis Pharma Serv. AG : Echocardiography in terms of clinical trial; Speaker fee; Advisory Board fee (2014) - Diamedica SIA : Heart failure. Honoraria (2014) - Berlin Chemie Menarini : Heart failure. Speaker fee (2014) - Bayer : Prevention of systemic embolism and stroke in AFib . Speaker fee (2014-2015)
Kaufmann Beat Andreas	Nothing to be declared (2013-2014-2015)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kerimkulova Alina	Nothing to be declared (2013-2014-2015)
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2013) - Boehringer-Ingelheim : cardiovascular (2013-2014-2015) - Daiichi Sankyo : cardiovascular (2013-2014-2015) - Medtronic : cardiovascular (2013-2014-2015) - Pfizer : cardiovascular (2013-2014-2015) - St Jude Medical : cardiovascular (2013-2014-2015) - Sanofi Aventis : cardiovascular (2013-2014-2015) - Meda pharma : cardiovascular (2013-2014-2015) - Bristol Myers Squibb : cardiovascular (2013-2014-2015) - Merck Sharp & Dohme : cardiovascular (2013-2014-2015) - Medscape : cardiovascular (2014-2015) - Bayer Healthcare : cardiovascular (2015) - Correvio : cardiovascular (2015) - Remedica : cardiovascular (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : cardiovascular (2013) - Bayer Healthcare : cardiovascular (2013) - Gilead : cardiovascular (2013) - BMS / Pfizer alliance : cardiovascular (2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : cardiovascular (2013-2014-2015) - Sanofi Aventis : cardiovascular (2013-2014-2015)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> - Meda pharma : cardiovascular (2013-2014-2015) - Daiichi Sankyo : cardiovascular (2014-2015) - British Heart Foundation : cardiovascular (2014-2015) - BMS / Pfizer alliance : cardiovascular (2014-2015) - Leducq Foundation : cardiovascular (2014-2015) - European Union FP7 : cardiovascular (2014-2015) - European Union horizon2020 : cardiovascular (2014-2015) - German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)
Kovask Sirje	Nothing to be declared (2013-2014-2015)
Lainscak Mitja	Nothing to be declared (2013-2014-2015)
Leite-Moreira Adelino	<p>Nothing to be declared (2014-2015)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Rosuvastatin (2013)
Linhartova Katerina	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Richter Gedeon : Pharmaceutic (2014-2015)
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astellas : atrial fibrillation, thrombosis (2013) - Biotronik : atrial fibrillation (2013-2014-2015) - Boehringer-Ingelheim : atrial fibrillation, thrombosis (2013-2014-2015) - Daiichi Sankyo : atrial fibrillation, thrombosis (2013-2014-2015) - Pfizer : atrial fibrillation, thrombosis (2013-2014-2015) - Bayer Healthcare : atrial fibrillation, thrombosis (2013-2014-2015)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lip Gregory Y H	<ul style="list-style-type: none"> - Bristol Myers Squibb : atrial fibrillation, thrombosis (2013-2014-2015) - Medtronic : atrial fibrillation (2014-2015) - Roche Diagnostics : anticoagulation (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer : atrial fibrillation, thrombosis (2013) - Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)
Macic-Dzankovic Amra	Nothing to be declared (2013-2014-2015)
Mestres Carlos A	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Cardiac valves (2013-2014-2015) - Symetis SA : Cardiac valves (2013-2014-2015) - On-X Life Technologies : Cardiac Valves (2013-2014-2015)
Metzler Bernhard	Nothing to be declared (2013-2014-2015)
Naber Christoph	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott : Absorb, DES, Mitraclip (2013-2014) - Biosensors : DES (2013-2014) - Meril Life Sciences : DES (2013-2014) - Biotronik : DES, BMS, DEB (2013-2014) - Medtronic : DES, TAVI (2013-2014) - Claret : Protection device (2013-2014) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - St Jude Medical : Renal Ablation, CRDM (2013-2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Biotronik : DEB/DES (2013-2014) - Stentys : DES (2013-2014) <p>Declaration not submitted (2015)</p>

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Nesukay Elena	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : cardiology (2013-2014-2015)
Nihoyannopoulos Petros	Nothing to be declared (2014-2015) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GSK : Consultant for Imaging studies (2013)
Obrenovic-Kircanski Biljana	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Hemofarm Stada (Serbia) : Honorary lectures for ACEI, ARB, beta blockers, CCB, (from 1997 to 2013, not in 2014) (2013-2014-2015)
Ozer Necla	Nothing to be declared (2013-2014-2015)
Paleev Filipp	Nothing to be declared (2013-2014) Declaration not submitted (2015)
Petriashvili Shalva	Nothing to be declared (2013-2014-2015)
Piepoli Massimo Francesco	Nothing to be declared (2013-2014-2015)
Punjabi Prakash	Nothing to be declared (2013-2014-2015)
Rapezzi Claudio	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : tafamidis, rare diseases (2013) - Merck Sharp & Dohme : ezetimibe (2014-2015) - Novartis : Heart Failure (2014-2015) - Pfizer : rare disease, tafamidis (2014-2015) - Servier : trimetazidine (2015) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabradine, HF and CAD (2013) D - Research funding (departmental or institutional). - Pfizer : Tafamidis (2013) - Pfizer : Tafamidis, rare diseases (2014-2015)
Rizk Hussien	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Hypertension (2013-2014)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Rizk Hussien	<ul style="list-style-type: none"> - Novartis : Hypertension and heart failure (2013-2014) - Novartis : Heart Failure (2015)
Rosenhek Raphael	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott : Valvular heart disease (2013-2014-2015) - Edwards Lifesciences : Valvular heart disease (2013-2014-2015) - Valtech : Valvular heart disease (2013-2014-2015) - Sorin Group : Valvular heart disease (2014-2015)
San Roman Calvar Jose Alberto	Nothing to be declared (2013-2014-2015)
Shapira Yaron	Nothing to be declared (2013-2014-2015)
Siebens Kaat	Nothing to be declared (2013-2014-2015)
Skoric Bosko	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott : Prograf (2013) - Astra Zeneca : Ranexa (2013) - Berlin Chemie AG : Ranexa (2013-2014) - Roche Diagnostics : agregometry (2014) - Servier : Corlantor (2014) - Astellas : Prograf (2014) - Astra Zeneca : ticagrelor (2014) - Krka Pharma : valsartan (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Novartis : valsartan (2015) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Takeda Pharmaceuticals : alogliptin (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Ministry of Science, Education and Sport of the Republic of Croatia : platelet function testing (2013-2014)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Skoric Bosko	<ul style="list-style-type: none"> - Teva Pharmaceutical Industries : sildenafil (2015) E - Research funding (personal). - Berlin Chemie AG : ranolazine (2015)
Stepinska Janina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : antiplatelet/ticagrelor (2013) - Pfizer : anticoagulation/apixaban (2013-2014) - Bristol Myers Squibb : anticoagulation/apixaban (2013-2014) - Abbott : ACS/stents (2013-2014-2015) - Boehringer-Ingelheim : anticoagulation/dabigatran (2013-2014-2015) - Bayer Healthcare : anticoagulation/rivaroxaban (2013-2014-2015) - Eli Lilly : Antiplatelet/prasugrel (2013-2014-2015) - Polpharma : heart failure/ beta blockers, ACE-inhibitors (2013-2014-2015) - Servier : heart failure/ivabradine (2013-2014-2015) - Berlin Chemie AG : hypertension (2014) - Novartis : heart failure/ relaxin (2014-2015) - Krka Pharma : hypertension, hyperlipidaemia (2014-2015) - Amgen : hyperlipidemia (2015) - Astra Zeneca : ticagrelor (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : ACS, registry (2013) - Bayer : atrial fibrillation, registry (2013) - Novartis : avute heart failure/relaxin (2013-2014-2015) - Servier : stable angina, registry (2013-2014-2015) - Bayer : atrial fibrillation, heart failure, rivaroxaban (2014-2015)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Stepinska Janina	<ul style="list-style-type: none"> - Janssen-Cilag : heart failure (2014-2015) - Cardioentis : heart failure (2014-2015) - Zoll Medical : STEMI/hypothermia (2014-2015)
Sudzhaeva Svetlana	Nothing to be declared (2013-2014-2015)
Tamargo Juan Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Menarini : Ranolazina (2013) - Menarini : Ranolazine (2014) - Menarini : Angina, diabetes (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca (Unrestricted Grant) : Candesartan, Felodipine, Atenolol (2014) - Servier : Committee Member (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : Unrestricted Grant (2013) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Instituto de Salud Carlos III. Ministerio de Economía y Competitividad. Gobierno de España : No product/device (2014)
Thilen Ulf Johan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Pulmonary hypertension (2013-2014-2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Gore : Atrial septal occluder (2013-2014-2015)
Turpeinen Anu	<p>Nothing to be declared (2014-2015)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Pulmonary arterial hypertension (2013)
Vanoverschelde Jean-Louis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medtronic : Valve (2013-2014) - Medtronic : Valve diseases (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sorin Group : Valve (2013-2014)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Vanoverschelde Jean-Louis	<ul style="list-style-type: none"> - Sorin : Valve diseases (2015) C - Receipt of royalties for intellectual property. <ul style="list-style-type: none"> - Edwards Lifesciences : Valve (2013-2014) - Edwards Life Sciences : Valve diseases (2015) D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Bayer : Unrestricted grant (2015) - Astrazeneca : Unrestricted grant (2015)
Varga Albert	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Actelion : pulmonary hypertension (2013-2014-2015) - AOP Orphan Pharmaceuticals : pulmonary hypertension (2015)
Vinereanu Dragos	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Lilly : ACS (2013) - Sandoz : CHD (2013) - Egis Pharma : Nicorandil (2013) - Daiichi Sankyo : Sevikar (2013) - Abbott : Omacor, Lypantyl (2013-2014) - Astra Zeneca : Brilique, Crestor, etc (2013-2014-2015) - Novartis : Cardiovascular prevention (2013-2014-2015) - GlaxoSmithKline : CHD (2013-2014-2015) - Servier : Corlentor, Prestarium, Prestance, Tertensif, etc (2013-2014-2015) - Sanofi Aventis : Diabetes (2013-2014-2015) - Bristol Myers Squibb : Eliquis (2013-2014-2015) - Medtronic : Interventional cardiology (2013-2014-2015) - Boehringer-Ingelheim : Pradaxa, Twinsta (2013-2014-2015)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Vinereanu Dragos	<ul style="list-style-type: none"> - Pfizer : Sortis, Eliquis (2013-2014-2015) - Berlin Chemie AG : Zomen, Nebilet, Leridip (2013-2014-2015) - A&D Pharma : Cardiovascular (2014-2015) - Vifor International : Heart failure (2014-2015) - Pfizer : NOAC (2014-2015) - Johnson & Johnson : NOAC (2014-2015) - Terapia : Sevikar (2014-2015) - Gedeon Richter : Hypertension (2015) - Bayer Healthcare : NOAC (2015) - Mylan (Abbott) : Omacor, Lypantyl (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Lilly : ACS (2013-2014-2015) - Sanofi Aventis : Diabetes (2013-2014-2015) - Bristol Myers Squibb : Eliquis (2013-2014-2015) - Novartis : Heart failure (2013-2014-2015) - Servier : Heart failure, CHD (2013-2014-2015) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Labormed : Indapamide (2013)
Wagner Kerstin	Nothing to be declared (2013-2014-2015)
Walker David Michael	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Heart Failure (2013-2014) - Novartis : Heart Failure (2013-2014-2015) - Astra Zeneca : Anti-platelet agents (2014) - Servier : Ivabradine (2015)

Guidelines on Infective Endocarditis 2015 (TF01) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zarzur Jamila	Nothing to be declared (2013-2014) Declaration not submitted (2015)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antithrombotics (2014) - Sanofi Aventis : Hyperlipidemia (2014) - Boehringer-Ingelheim : Oral anticoagulation (2014) - Pfizer/BMS alliance : Oral anticoagulation (2014) - Novartis : Hypertension (2014-2015) - Bayer Healthcare : Oral anticoagulation (2014-2015) - Merck Sharp & Dohme : Antithrombotics (2015)
Achenbach Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation (2013) - Behring : Anticoagulation (2013) - Astra Zeneca : Antiplatelet Therapy (2013) - Abbott : Coronary Intervention (2013) - Siemens Healthcare : CT (2013) - Servier : Imaging (2013) - Guerbet : Imaging (2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Abbott : Coronary Intervention (2013-2014) - Siemens Healthcare : Imaging (2013-2015)
Agewall Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Böhringer Ingelheim : Anticoagulatn treatment (2013) - Roche Diagnostics : Cardiac markers (2013) - Orion : Heart failure (2013)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Agewall Stefan	<ul style="list-style-type: none"> - Pfizer : Lipids (2013) - Sanofi Aventis : Lipids (2013) - Siemens Healthcare : Markers (2013) - Astra Zeneca : Platelet inhibition (2013-2014-2015) - Thermo Fischer Scientific : Cardiac markers (2014-2015)
Badimon Lina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : cardiovascular (2013) - Sanofi Aventis : cardiovascular (2013) - MSD-España : Lipids (2014) - Sanofi Aventis : lipids (2014-2015) - Burson Masteller : nutrition (2014-2015) - Astra Zeneca : thrombosis (2014-2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astrazeneca : thrombosis (2014-2015)
Baron Esquivias Gonzalo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation (2013-2014-2015) - Boehringer-Ingelheim : Anticoagulation (2013-2014-2015) - Daiichi Sankyo : Anticoagulation (2013-2014-2015) - Pfizer : Anticoagulation (2013-2014-2015) - Menarini : Ischemic disease (2015) - Laboratorios Rovi : Ivabradine (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Biotronik : Vasovagal syncope & Pacing (2013) - Bayer : Anticoagulation (2015)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014-2015) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015) - Abbott : transcatheter mitral valve repair (Mitraclip) (2013-2014-2015) - Edwards Lifesciences : transcatheter valve implantation (2013-2014-2015) - Direct Flow Medical : transcatheter valve implantation (2013-2014-2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Actelion : Bosentan for PAH treatment in congenital heart disease (2013-2014-2015) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015) - Abbott : transcatheter mitral valve repair (Mitraclip) (2013-2014-2015) - Edwards Lifesciences : transcatheter valve implantation (2013-2014-2015) - Direct Flow Medical : transcatheter valve implantation (2013-2014-2015)
Bax Jeroen	<p>Nothing to be declared (2014-2015)</p> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Servier : Farma (2013) - Edwards Lifesciences : Heart Valves (2013) - GE Healthcare : Imaging (2013) - Lantheus Inc : Imaging (2013) - Boston Scientific : Pacing (2013) - Medtronic : Pacing (2013) - St Jude Medical : Pacing (2013) - Biotronik : Pacing (2013)
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - BMS/Pfizer : Apixaban (2013)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> - Roche Pharma : Dalcetrapib (2013) - Novartis : Relaxin (2013) - Bayer Healthcare : Aspirin, rivaroxaban (2013-2014-2015) - Sanofi Aventis : Clopidogrel (2013-2014-2015) - Daiichi Sankyo : Prasugrel (2013-2014-2015) - Eli Lilly : Prasugrel (2013-2014-2015) - Astra Zeneca : Ticagrelor (2013-2014-2015) - Novartis : Serelaxin (2014) - Pfizer : Apixaban (2014-2015) - Bristol Myers Squibb : Apixaban (2014-2015) - Servier : ivabradine (2014-2015) - Menarini : Ranolazine (2014-2015) - Abbott : Absorb stent (2015) - Novartis : Serelaxin, ACZ696 (2015) - Ferrer Internacional : Trinomia (polypill) (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2013-2014-2015)
Carerj Scipione	Nothing to be declared (2013-2014-2015)
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Hypertension (2013-2014-2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Menarini : Hypertension (2013-2014-2015)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Fitzsimons Donna	Nothing to be declared (2013-2015) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : FH Treatment options (2014)
Gaemperli Oliver	Nothing to be declared (2013) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : Stents (2014) - Biosensors : Axxess Bifurcation Stent (2015) - Abbott Vascular : MitraClip (2015) - Biosensors : Travel Grant to AsiaPCR 2015 (2015)
Kirchhof Paulus	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2013) - Boehringer-Ingelheim : cardiovascular (2013-2014-2015) - Daiichi Sankyo : cardiovascular (2013-2014-2015) - Medtronic : cardiovascular (2013-2014-2015) - Pfizer : cardiovascular (2013-2014-2015) - St Jude Medical : cardiovascular (2013-2014-2015) - Sanofi Aventis : cardiovascular (2013-2014-2015) - Meda pharma : cardiovascular (2013-2014-2015) - Bristol Myers Squibb : cardiovascular (2013-2014-2015) - Merck Sharp & Dohme : cardiovascular (2013-2014-2015) - Medscape : cardiovascular (2014-2015) - Bayer Healthcare : cardiovascular (2015) - Correvio : cardiovascular (2015) - Remedica : cardiovascular (2015)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : cardiovascular (2013) - Bayer Healthcare : cardiovascular (2013) - Gilead : cardiovascular (2013) - BMS / Pfizer alliance : cardiovascular (2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : cardiovascular (2013-2014-2015) - Sanofi Aventis : cardiovascular (2013-2014-2015) - Meda pharma : cardiovascular (2013-2014-2015) - Daiichi Sankyo : cardiovascular (2014-2015) - British Heart Foundation : cardiovascular (2014-2015) - BMS / Pfizer alliance : cardiovascular (2014-2015) - Leducq Foundation : cardiovascular (2014-2015) - European Union FP7 : cardiovascular (2014-2015) - European Union horizon2020 : cardiovascular (2014-2015) - German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - B.Braun : Surgical instruments (2013-2014) - Astra Zeneca : Antiplatelet agents (2013-2014-2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : Cardiac valves (2013) - Boston Scientific : Coronary stents (2013) - Siemens Healthcare : Medical imaging (2013) - Johnson & Johnson : Thoracoscopic devices (2013)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kolh Philippe H	<ul style="list-style-type: none"> - Edwards Lifesciences : Cardiac valves (2013-2014-2015) - Medtronic : Cardiac valves (2013-2014-2015)
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier : Heart Failure (2013) - Abbott : MitraClip (2013) - Menarini : nebivolol (2014) - St Jude Medical : Heart Failure (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astrazeneca : Dyslipidemia (2013) - Boston Scientific : CRT (2014) - Servier : procoralan (2014) - Daiichi Sankyo : Teaching course on imaging (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Actelion : Pulmonary Hypertension (2013)
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astellas : atrial fibrillation, thrombosis (2013) - Biotronik : atrial fibrillation (2013-2014-2015) - Boehringer-Ingelheim : atrial fibrillation, thrombosis (2013-2014-2015) - Daiichi Sankyo : atrial fibrillation, thrombosis (2013-2014-2015) - Pfizer : atrial fibrillation, thrombosis (2013-2014-2015) - Bayer Healthcare : atrial fibrillation, thrombosis (2013-2014-2015) - Bristol Myers Squibb : atrial fibrillation, thrombosis (2013-2014-2015) - Medtronic : atrial fibrillation (2014-2015) - Roche Diagnostics : anticoagulation (2015)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lip Gregory Y H	D - Research funding (departmental or institutional). - Bayer : atrial fibrillation, thrombosis (2013) - Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)
Nihoyannopoulos Petros	Nothing to be declared (2014-2015) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GSK : Consultant for Imaging studies (2013)
Piepoli Massimo Francesco	Nothing to be declared (2013-2014-2015)
Ponikowski Piotr	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : anticoagulant (2013) - Bristol Myers Squibb : anticoagulant (2013) - ROSCHE : diabetes (2013) - Boehringer-Ingelheim : anticoagulant (2013-2014) - Respicardia : anticoagulant (2013-2014) - Johnson & Johnson : heart failure (2013-2014) - Pfizer : heart failure, anticoagulant (2013-2014) - Abbott Vascular : devices (2013-2014-2015) - Novartis : heart failure (2013-2014-2015) - Cardioentis : heart failure (2013-2014-2015) - Bayer Healthcare : heart failure (2013-2014-2015) - Vifor Pharma ltd : heart failure (2013-2014-2015) - CIBIEM : heart failure (2013-2014-2015) - Servier : heart failure, coronary artery disease (2013-2014-2015) - Amgen : heart failure, lipids (2013-2014-2015) - MSD : lipids (2014)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> - Astra Zeneca : acute coronary syndrome (2014-2015) - Boehringer-Ingelheim : anticoagulant, diabetes (2015) - Respicardia : devices (2015) - BioControl : devices (2015) - DC Device : devices (2015) - Celladon : heart failure (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Vifor Pharma ltd : heart failure (2014) - MSD : lipids (2014) - Astra Zeneca : acute coronary syndrome (2014-2015) - Respicardia : anticoagulant (2014-2015) - Novartis : heart failure (2014-2015) - Cardiorentis : heart failure (2014-2015) - Bayer Healthcare : heart failure (2014-2015) - CIBIEM : heart failure (2014-2015) - Servier : heart failure, coronary artery disease (2014-2015) - Amgen : heart failure, lipids (2014-2015) - BioControl : devices (2015) - DC Device : devices (2015) - Celladon : heart failure (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Vifor Pharma ltd : heart failure (2013) - Singulex : biomarkers (2015)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : antiplatelet therapy (2013) - Lilly : antiplatelet therapy (2013) - Astra Zeneca : antiplatelet therapy (2013) - Johnson & Johnson : coronary catheters (2014) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Biosensors : devices (2013-2014-2015) - Boston Scientific : devices (2013-2014-2015) - Medtronic : devices (2013-2014-2015) - Biotronik : devices (2013-2014-2015) - Abbott Vascular : devices (2013-2014-2015)
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Pulmonary arterial hypertension (2013-2014-2015) - GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2013-2014-2015) - Lilly : pulmonary arterial hypertension - ambrisentan (2013-2014-2015) - Actelion : pulmonary arterial hypertension - macitentan, selexipag (2013-2014-2015) - Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2013-2014-2015) - AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Pulmonary hypertension (2013-2014-2015)
Vaz Carneiro Antonio	<p>Nothing to be declared (2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - AbbVie : Oncology (2013-2014)
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet drug (2013) - Eli Lilly : Antiplatelet drug (2013)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Abbott : Stent (2013) - Medtronic : Stent (2013) - Biotronik : Stent (2013) - Astra Zeneca : Antiplatelet therapy (2014-2015) - Eli Lilly : Antiplatelet therapy (2014-2015) - Bayer Healthcare : Antithrombotic drug (2014-2015) - Abbott : Stent and Heartvalvetherapy (2014-2015) - Biosensors : Stents (2014-2015) - Boston Scientific : Stents (2014-2015) - Medtronic : TAVI, Stent (2015) - Edwards Lifesciences : Transcatheter heart valves (2015) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - St Jude Medical : OCT (2013-2014-2015) - Biotronik : Stent (2013-2014-2015) - Medtronic : Stent and Heartvalves (2014) - Medicines Company : Antithrombotic therapy (2014-2015) - Johnson & Johnson : Catheters (2014-2015) - Edwards Lifesciences : Heartvalves (2014-2015) - Abbott : Stent (2014-2015) - Boston Scientific : Stent and Heartvalves (2014-2015)
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Daiichii : Atrial Fib (2013) - Merck Sharp & Dohme : Lipid Lowering (2013)

Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<ul style="list-style-type: none"> - Philips : 3D echo (2014) - Toshiba medical imaging : fusion imaging 3D echo CT (2014) - Astra Zeneca : Speaker fee for 1 talk in 2014 (2014) - MSD : CV risk factors (2014-2015) - Abbott : Lecturing (2015) - Astra Zeneca : Lecturing (2015) - Pfizer : Lecturing (2015) - Sorin Group : Respicardia echo protocol (2015) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - European Research FP7 : CV Imaging (2013) - Servier : Imaging in ISchemic patients (2013) - Siemens Healthcare : 3d echo software and free style echo (2014-2015) - Toshiba medical imaging : Fusion Imaging (2015) <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Springer : ESC Textbook of CV Imaging (2013) <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Amgen : Clinical trial (2014-2015) - Novartis : Clinical trial (2014-2015) - Ikaria : Clinical trial (2014-2015)